Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Other

Hearing loss

Neurotrophic tyrosine kinase receptor 2 (NTRK2; TrkB)

In vitro and mouse studies suggest TrkB agonists could help treat hearing loss. In neurotrophin-depleted cochlear cultures, TrkB agonists increased survival of spinal ganglion neurons (SGNs) compared with no treatment. In patch-clamp studies on auditory SGNs, pretreatment with TrkB agonists increased currents compared with no treatment. In a mouse model of deafness, TrkB agonists decreased electrically evoked auditory response thresholds and increased SGN density. Next steps include preclinical and IND-enabling studies of a TrkB agonist prodrug.

SciBX 6(34); doi:10.1038/scibx.2013.935
Published online Sept. 5, 2013

Patent application filed; available for licensing

Yu, Q. et al. J. Neurosci.;
published online Aug. 7, 2013;
doi:10.1523/JNEUROSCI.0854-13.2013
Contact: Xi Lin, Emory University School of Medicine, Atlanta, Ga.
e-mail:
xlin2@emory.edu
Contact: Keqiang Ye, same affiliation as above
e-mail:
kye@emory.edu